Drugs / Bivalent subtype C gp120/AS01(B)
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03122223 Comparator | Jan 2018 → Jul 2020 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bivalent subtype C gp120/AS01(B) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03122223 ↗ |
| Modality | Vaccine | “bivalent gp120 protein/AS01(B) vaccine regimens” NCT03122223 ↗ |
| Route | Intramuscular | “administered IM as a single 0.75 mL dose” NCT03122223 ↗ |